Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol vs sufentanil for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery
ChiCTR2600116664Phase 4Not yet recruiting
- Sponsor
- International Peace Maternity and Child Health Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tapentadol in postoperative nausea and vomiting (PONV) and postoperative pain (2 arms), sponsored by International Peace Maternity and Child Health Hospital. Primary endpoint: Incidence of nausea and vomiting within 24 hours after surgery. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tapentadol
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on ChiCTR2600116664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116664.